Form SCHEDULE 13G/A X4 Pharmaceuticals, Inc Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260814/26932870.html

Form SCHEDULE 13G/A X4 Pharmaceuticals, Inc Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260814/26932870.html

Form SCHEDULE 13G/A X4 Pharmaceuticals, Inc Filed by: Deep Track Capital, LP

Fri, 14 Aug 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26925215.html

Form SCHEDULE 13G/A X4 Pharmaceuticals, Inc Filed by: Deep Track Capital, LP

Fri, 14 Aug 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26925215.html

Form 4 X4 Pharmaceuticals, Inc For: Aug 12 Filed by: Volpone John

Thu, 13 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260813/26921209.html

Form 4 X4 Pharmaceuticals, Inc For: Aug 12 Filed by: Volpone John

Thu, 13 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260813/26921209.html

Form 4 X4 Pharmaceuticals, Inc For: Aug 12 Filed by: Craig Adam R

Thu, 13 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26921098.html

Form 4 X4 Pharmaceuticals, Inc For: Aug 12 Filed by: Craig Adam R

Thu, 13 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26921098.html

Form 144 X4 Pharmaceuticals, Inc Filed by: Craig Adam R

Thu, 13 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260813/26920473.html

Form 144 X4 Pharmaceuticals, Inc Filed by: Craig Adam R

Thu, 13 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260813/26920473.html

Form 144 X4 Pharmaceuticals, Inc Filed by: Volpone John

Thu, 13 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260813/26920486.html

Form 144 X4 Pharmaceuticals, Inc Filed by: Volpone John

Thu, 13 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260813/26920486.html

X4 Pharmaceuticals (XFOR) Tops Q2 EPS by 6c

Thu, 06 Aug 2026 16:20:56 -0400

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q2 EPS of ($0.13), $0.06 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $8.81 million versus the consensus estimate of $2.28 million.

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 06 Aug 2026 16:15:00 -0400

- Strengthened Clinical Operations to Continue Progress in Enrolling Global 4WARD Phase 3 Chronic Neutropenia Trial -

- European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union -

- Balance Sheet Provides Cash Runway

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 06 Aug 2026 16:15:00 -0400

- Strengthened Clinical Operations to Continue Progress in Enrolling Global 4WARD Phase 3 Chronic Neutropenia Trial -

- European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union -

- Balance Sheet Provides Cash Runway

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 06 Aug 2026 16:15:00 -0400

- Strengthened Clinical Operations to Continue Progress in Enrolling Global 4WARD Phase 3 Chronic Neutropenia Trial -

- European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union -

- Balance Sheet Provides Cash Runway

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 06 Aug 2026 16:15:00 -0400

- Strengthened Clinical Operations to Continue Progress in Enrolling Global 4WARD Phase 3 Chronic Neutropenia Trial -

- European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union -

- Balance Sheet Provides Cash Runway

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 06 Aug 2026 16:15:00 -0400

- Strengthened Clinical Operations to Continue Progress in Enrolling Global 4WARD Phase 3 Chronic Neutropenia Trial -

- European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union -

- Balance Sheet Provides Cash Runway

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 06 Aug 2026 16:15:00 -0400

- Strengthened Clinical Operations to Continue Progress in Enrolling Global 4WARD Phase 3 Chronic Neutropenia Trial -

- European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union -

- Balance Sheet Provides Cash Runway

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 06 Aug 2026 16:15:00 -0400

- Strengthened Clinical Operations to Continue Progress in Enrolling Global 4WARD Phase 3 Chronic Neutropenia Trial -

- European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union -

- Balance Sheet Provides Cash Runway

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 06 Aug 2026 16:15:00 -0400

- Strengthened Clinical Operations to Continue Progress in Enrolling Global 4WARD Phase 3 Chronic Neutropenia Trial -

- European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union -

- Balance Sheet Provides Cash Runway

Form 10-Q X4 Pharmaceuticals, Inc For: Jun 30

Thu, 06 Aug 2026 16:09:00 -0400
si-local-file:///var/storage/secattach/20260806/26883886.html

Form 10-Q X4 Pharmaceuticals, Inc For: Jun 30

Thu, 06 Aug 2026 16:09:00 -0400
si-local-file:///var/storage/secattach/20260806/26883886.html

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 03 Aug 2026 16:30:00 -0400

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on July 31, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 12,000 shares of X4’s common

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 03 Aug 2026 16:30:00 -0400

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on July 31, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 12,000 shares of X4’s common

StreetInsider.com News Articles

Form SCHEDULE 13G/A X4 Pharmaceuticals, Inc Filed by: PERCEPTIVE ADVISORS LLC

Form SCHEDULE 13G/A X4 Pharmaceuticals, Inc Filed by: PERCEPTIVE ADVISORS LLC

Form SCHEDULE 13G/A X4 Pharmaceuticals, Inc Filed by: Deep Track Capital, LP

Form SCHEDULE 13G/A X4 Pharmaceuticals, Inc Filed by: Deep Track Capital, LP

Form 4 X4 Pharmaceuticals, Inc For: Aug 12 Filed by: Volpone John

Form 4 X4 Pharmaceuticals, Inc For: Aug 12 Filed by: Volpone John

Form 4 X4 Pharmaceuticals, Inc For: Aug 12 Filed by: Craig Adam R

Form 4 X4 Pharmaceuticals, Inc For: Aug 12 Filed by: Craig Adam R

Form 144 X4 Pharmaceuticals, Inc Filed by: Craig Adam R

Form 144 X4 Pharmaceuticals, Inc Filed by: Craig Adam R

Form 144 X4 Pharmaceuticals, Inc Filed by: Volpone John

Form 144 X4 Pharmaceuticals, Inc Filed by: Volpone John

X4 Pharmaceuticals (XFOR) Tops Q2 EPS by 6c

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Form 10-Q X4 Pharmaceuticals, Inc For: Jun 30

Form 10-Q X4 Pharmaceuticals, Inc For: Jun 30

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)